Cara Therapeutics Long Term Debt

Cara Therapeutics's long-term debt stands at $22K as of June 2026. That compares with $150K in the prior-year period — down 84.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Cara Therapeutics reported $22K in long-term debt versus $150K a year earlier — a 84.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $150K in the prior-year period — down 84.8% year over year. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Cara Therapeutics's long-term debt evolved across reporting periods, while the comparison chart places CARA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, long-term debt is commonly used to spot outliers. Cara Therapeutics's reading of $22K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.